

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, CANADA, JAPAN OR ANY OTHER JURISDICTION WHERE IT IS UNLAWFUL TO DISTRIBUTE THIS ANNOUNCEMENT



This announcement is an advertisement and not a prospectus and not an offer of securities for sale in any jurisdiction, including in or into Egypt, the United States, Australia, Canada or Japan. Neither this announcement, nor anything contained herein, shall form the basis of, or be relied upon in connection with, any offer or commitment whatsoever in any jurisdiction. Investors in the International Offering (as defined below) should not subscribe for or purchase any shares referred to in this announcement except solely on the basis of the information contained in an offering circular expected to be published in due course (the "Offering Circular").

Macro Group Pharmaceuticals (Macro Capital) S.A.E. announces its intention for a public offering of ordinary shares on the Egyptian Exchange

Cairo, 2 March 2021

Macro Group Pharmaceuticals (Macro Capital) S.A.E. ("Macro Group", "Macro", the "Company" or the "Issuer"), the largest and one of the fastest growing cosmeceutical companies in Egypt, announced today its intention to proceed with an initial public offering (the "IPO" or the "Offering") and list its shares on the Egyptian Exchange (the "EGX").

The Offering is expected to consist of a secondary sale by Leo 1 (the "Selling Shareholder") of up to 282,905,665 existing ordinary shares on the EGX, representing up to 49% of the Company's share capital and will include:

- (i) A private placement to certain institutional investors in several countries, including Egypt (the "International Offering"); and
- (ii) A retail offering to retail investors in Egypt (the "Egyptian Retail Offering")

Both the International Offering and Egyptian Retail Offering (the "Combined Offering") will be offered at the same price per share (the "Offer Price").

Established in 2005, Macro Group leads Egypt's fast-growing cosmeceuticals space with a market share of 23.1% recorded in 2020¹. The Company's EBITDA grew by a 2018-20 CAGR of 92% to EGP 187 million² in what was a challenging pandemic year, testament to the Company's defensive demand-profile, robust business model, and resilient growth strategy, which combined are expected to drive future growth in this new stage of its corporate evolution. Macro Group boasts a diversified portfolio of 125 marketed SKUs, which consists of 124 cosmeceutical SKUs across seven therapeutic areas and one nutraceutical SKU, which was launched in December 2020. While all of the Company's products are available over-the-counter ("OTC"), Macro also utilizes a prescription-based sales strategy and generates demand through an incentivized medical salesforce of over 550 employees that targets physicians and pharmacies nationwide. 85% of sales are estimated to be initially generated via prescription at the physician level, underlining the defensive demand-profile of Macro Group's business. Meanwhile, an advantageous regulatory framework enables the Company to leverage its extensive in-house innovation capabilities, having developed an extensive pipeline of 79 products across a variety of high-growth, high-margin cosmeceutical and nutraceutical therapeutic areas, which are expected to be launched between Q1 2021 and Q2 2023.

Macro Group is in the process of obtaining the required approvals and registrations related to the Combined Offering, including from the Egyptian Financial Regulatory Authority (the "FRA") and the EGX. Completion of the Combined Offering is expected to take place late Q1 2021/early Q2 2021, subject to market conditions and the timely receipt of the relevant regulatory approvals.

CI Capital Investment Banking S.A.E ("CI Capital") and Renaissance Capital Egypt for Promoting and Underwriting of Securities S.A.E. ("Renaissance Capital") have been appointed as Joint Global Coordinators and Joint Bookrunners, while White & Case ("White & Case") has been appointed as international and local (in association with MHR & Partners) counsel to the Issuer. Dechert LLP and Zaki Hashem & Partners are counsels to the Joint Global Coordinators and Joint Bookrunners.

¹ Source: IQVIA Cosmo View report. Data takes into account Skin Care, Hair Care, Oral Care, Female Intimate Care, Intimate Care, Anti-Scar, Antiseptics, and Topical Muscle Relaxants

² Profit for the year before net finance cost, income tax expense, depreciation, amortization and impairment losses on financial assets

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, CANADA, JAPAN OR ANY OTHER JURISDICTION WHERE IT IS UNLAWFUL TO DISTRIBUTE THIS ANNOUNCEMENT



Commenting on the Offering, the Company's Chairman and Co-founder, Dr. Ahmed El Nayeb, said: "I am extremely proud of the organization we have built over the last 18 years, from its humble beginnings to becoming the market leader in Egypt's cosmeceutical space and the first of its kind to go public in Egypt. With a leading local market position achieved within 5 of the 7 therapeutic areas in which we operate, the upcoming IPO will mark yet another significant milestone for our business and the next phase in the Company's growth strategy as we look to deliver on our vision of becoming a leading regional provider of both cosmeceuticals and nutraceuticals. Our ambition is to leverage our customer-centric business model, extensive manufacturing capabilities and nationwide sales and distribution network to deliver sustainable growth and generate value for all our stakeholders"

The Company's Vice Chairman, Ahmed Rady, added: "I am delighted to announce the upcoming listing of Macro Group on the Egyptian Exchange. Since our investment in 2017, we have worked alongside our relentless management team to supercharge sustainable growth, expand operating margins, and lay the foundations for a more impressive future. We have successfully grown our gross profit margin from 63% in 2018, to 79% in 2020, grown our EBITDA margin from 21% in 2018 to 43% in 2020, and have achieved an impressive EBITDA CAGR of 92% over the same period. We operate in an industry that is witnessing transformational growth driven by increasing consumer adoption and rising income levels which drive industry growth. With our consumer-centric innovation capabilities always positioning us at the forefront of the market, coupled with our sales and distribution muscle, we believe that Macro Group will continue to shape what is a thriving and high growth market, and are excited for what the future holds for us."

The Company's Chief Executive Officer, Dr. Hisham Wasfy, added: "With revenues and net profit up by a 2018-20 CAGR of 34% and 98% respectively, Macro has shown tremendous growth in recent years driven by innovative new launches, which were further supported by our enhanced sales capabilities and distribution platforms. We were able to ramp up sales while remaining capex-light on the back of clearly-defined growth avenues, which includes our recent expansion into nutraceuticals, growing our regional footprint, the development and promotion of higher-priced products, and new direct-to-consumer marketing initiatives. At Macro Group, we believe in our value-driven culture and our team's ability to innovate and maximize our operational and strategic potential, enabling us to achieve sustainable commercial success and consistent top line growth. I am honoured to lead a Company at the forefront of Egypt's burgeoning cosmeceutical industry and am grateful to Macro's team across Egypt for their shared commitment to our vision."

For further information, please contact:

Company

Macro Group Pharmaceuticals

Ahmed Amr

Investor Relations Officer and Finance Manager

ahmed.amr@macro-egy.com

macro-egy.com

Joint Global Coordinators & Bookrunners

Renaissance Capital

Amr Helal: AHelal@rencap.com

Simon Aird: SAird@rencap.com

Omar Gaafar: OGaafar@rencap.com

CI Capital

Adel Abbas: adel.abbas@cicapital.com

Malak Dow: malak.dow@cicapital.com

Ahmed El Soueni: ahmed.elsoueni@cicapital.com

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, CANADA, JAPAN OR ANY OTHER JURISDICTION WHERE IT IS UNLAWFUL TO DISTRIBUTE THIS ANNOUNCEMENT



About the Selling Shareholder

Macro Group is 99.9% owned by Leo 1, an investment vehicle incorporated in Mauritius. Leo 1 is approximately 19.7% indirectly-owned by Enverson International Company (“Enverson”), a vehicle owned by the Company’s co-founder, Dr. Ahmed El Nayeb and family, 0.9% indirectly owned by Dr. Ahmed El Nayeb and 79.5% indirectly owned by MEA Healthcare Partners Ltd. (“MEA Healthcare”), a co-investment vehicle funded by a consortium of institutional investors, including Kingsway Capital (“Kingsway”) and Alta Semper Capital (“Alta Semper”)³.

About Macro Group Pharmaceuticals (Macro Capital) S.A.E.

Macro Group is one of the largest and fastest growing cosmeceutical companies in Egypt. The Company is principally engaged in the manufacture and sale of a wide range of cosmeceutical products (through both prescription and OTC sales) and, to a lesser extent, nutraceuticals, which include nutritional food supplements. By developing its own branded and proprietary products, Macro Group offers an attractive value proposition by combining the advantageous regulatory framework of cosmetics with the defensive attributes and demand profile of prescription-based pharmaceuticals.

After a preliminary development phase of around three years, Macro Group was established in 2005 as a joint partnership by Dr. Ahmed El Nayeb and his partner (the “Founders”). In its early stages, the Company’s product portfolio included a mix of dietary supplements and cosmeceutical products which were all toll manufactured in other production facilities through an asset light model. Starting in 2007, the Company shifted its focus exclusively to cosmeceuticals, where a promising gap in the market was identified, and innovation was facilitated by an attractive regulatory framework. To accommodate the growing demand for its cosmeceutical products over the subsequent years, Macro Group established its first production facility in 2010 and shifted to in-house production. By 2016, with an enhanced portfolio of 45 SKUs, a headcount of more than 600 employees and revenues exceeding the EGP 200 million-mark, the Company had evolved into a leading player in Egypt’s cosmeceuticals industry. The following year, MEA Healthcare indirectly acquired a 60% stake from the Founders, with a plan to transform Macro Group into a high-growth institutionalized business with a strong governance structure in place. In 2020, MEA Healthcare subsequently increased its stake in the Company by acquiring one of the Founders’ 19.5% stake in Macro Group, thereby increasing its shareholding in Macro Group to 79.5%³.

Today, the Company is a leader in Egypt’s cosmeceutical space, catering to multiple demographic segments and ranking first in terms of sales, with a 23.1% overall market share recorded in 2020⁴. Revenues were EGP 431mn in 2020, more than doubling the 2016 level, with innovative launches being the chief cornerstone of the Company’s growth. The Company has developed an attractive portfolio of 124 high-margin SKUs, across seven high-growth therapeutic areas⁵, including Skin Care, Hair Care, Female Intimate Care, Anti-scar, Oral Care, Antiseptics, Topical Muscle Relaxants and one nutraceutical product. Further, the Company has developed a pipeline of 79 new SKUs in cosmeceutical and nutraceutical therapeutic areas to be launched between Q1 2021 and Q2 2023. The Company’s cosmeceutical products are manufactured in-house at its 3,578 sqm production facility located in Badr City. The facility has a quality assurance system and has been awarded multiple ISO accreditations, indicative of the Company’s dedication to product quality and facility hygiene and safety.

Macro Group has adopted an innovative, prescription-based and consumer-centric model centred around demand creation and distribution by focusing on physicians as the main drivers of business, which is supplemented by pharmacies and OTC sales channels, with a wide geographical reach. The Company enjoys extensive coverage of physicians across a range of specialties, comprising approximately 16,000 physicians, which represented 30% of the Company’s targeted physicians within its therapeutic areas as of 2020, and a wide coverage of pharmacies across its distribution channels, comprising approximately 60,000 pharmacies, which represented 86% of pharmacies in Egypt as of 2020⁶. Macro Group has implemented a diversified distribution and sales strategy and is particularly focused on leveraging its direct distribution channels, which require lower working capital and yield higher margins. Out of the Company’s total sales in 2020, direct distribution channels represented 62.2% (23.5% to pharmacies and 38.7% to wholesalers), indirect distribution channels represented 35.9% (through the Company’s key distributors in Egypt), while export sales represented the remaining 1.9%³. Its recently expanded distribution network ensures that the Company

³ Rounded to one decimal place

⁴ Source: IQVIA Cosmo View report. Data takes into account Skin Care, Hair Care, Oral Care, Female Intimate Care, Intimate Care, Anti-Scar, Antiseptics, and Topical Muscle Relaxants

⁵ Excluding Lactagogue, a new therapeutic area under which the Company launched its first nutraceutical product in December 2020. See “Growth Strategy” for more information

⁶ Source: Fitch Solutions (previously known as Business Monitor International)

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, CANADA, JAPAN OR ANY OTHER JURISDICTION WHERE IT IS UNLAWFUL TO DISTRIBUTE THIS ANNOUNCEMENT



enjoys nationwide geographical presence in Egypt's highly populated areas, such as Cairo, Giza, Alexandria, Delta, Fayoum, Beni Suef, Minya, Assiut, Sohag, Qena, Luxor and Aswan.

The Company also exports its products to markets across the Middle East and Africa ("MEA") through arrangements with on-the-ground distributors, agencies and large pharmaceutical chains. With revenues from exports contributing just 1.9%³ to overall revenues, in 2020, Macro Group's business model presents an opportunity for further regional expansion on the back of a solid track record and necessary knowledge-base.

Competitive Strengths

Largest player in a large, underserved local market with high growth prospects

In Egypt, rising wealth, increased urbanization, higher internet and smartphone penetration, and fast-growing private consumption levels have fuelled local demand for premium, innovative cosmeceutical products. Moreover, as a hybrid between cosmetics and pharmaceutical products, cosmeceuticals enjoy a relatively more flexible regulatory framework associated with cosmetics, including fast product registration and free pricing, combined with the inelastic demand profile of pharmaceuticals. As a result, cosmeceutical sales in Egypt grew at an overall 5-year CAGR of 35%, compared to a CAGR of 21% for the pharmaceutical sector during the same period.

Macro Group is a leading player in Egypt's dynamic cosmeceuticals sector, commanding a top value market share of 23.1% in 2020, with the remaining fourteen top-ranked players in Egypt, both local and international, each recording market shares of less than 10% across the board, and the Company achieving more than three times the value market share of that of its closest local competitor⁷. The Company has achieved its leading position in the Egyptian cosmeceuticals market through its innovative and attractive consumer-centric business model that has enabled the Company to leverage its in-house market intelligence and innovation initiatives to continuously launch new products at attractive price points for customers in different demographic segments of the Egyptian population, all while enjoying nationwide geographical coverage through its robust sales capabilities and efficient distribution platforms.

Leading position across some of the most attractive therapeutic areas of the market

Macro Group boasts a highly attractive portfolio of market leading brands across key and high growth therapeutic areas which have shown considerable growth in Egypt in recent years, with their respective 5-year market value CAGRs coming in within the 24-41% range. The Company enjoys the leading position within the Female Intimate Care space (2020 market share: 56%), Oral Care (2020 market share: 40%), Skin Care (2020 market share: 33%), Antiseptics (2020 market share: 28%) and Hair Care (2020 market share: 19%) during the same period⁷. Revenue from the Company's top five selling brands grew at a 2018-20 CAGR of 40%⁸, with its two top brands, Gold (Female Intimate Care) and Orovex (Oral Care), ranked first in the market within their respective therapeutic areas in terms of sales during 2020⁷.

While antiseptics (excluding exports) represented only 6% of the company's total revenues in 2020, it was the Company's fastest growing therapeutic area during the year on the back of increasing market demand for hygiene and sanitary products throughout the COVID-19 pandemic, with its sales value (excluding exports) growing by an exceptional 83% y-o-y, coupled with 47% y-o-y in sales volume growth over the same period.

Modern production facility with significant room for expansion and minimal investment requirements

Macro Group manufactures most of its products in its modern production facility in Badr City. The facility houses 10 state-of-the-art production lines, in addition to ancillary packaging machinery, and is constructed in accordance with Good Manufacturing Practices ("GMP") and Good Laboratory Practices ("GLP"). Its annual production capacity is currently at 49mn units based on two shifts, bringing its 2020 utilization rate to 34%. The Company has successfully maintained a low CAPEX to sales ratio, which came in at just 0.02x in 2020 and remained significantly below that of local and international publicly-traded peers in both the cosmeceutical and pharmaceutical industries. Going forward, the Company's management does not foresee significant capital investments required in the medium term to accommodate its growth strategy.

Robust sales capabilities and efficient distribution platforms

Macro Group markets its products through a highly capable and incentivized salesforce of over 550 employees, comprising a promotion team and a distribution team. With 85% of sales estimated to be initially generated via prescriptions in 2020, the promotion team generates demand by engaging directly with a target network of approximately

⁷ Source: IQVIA Cosmo View report. Data takes into account Skin Care, Hair Care, Oral Care, Female Intimate Care, Intimate Care, Anti-Scar, Antiseptics, and Topical Muscle Relaxants

⁸ Represents the 2-year CAGR based on the top 5 brand's contribution to total net sales



16,000 physicians, with around 445,000 physician visits made in 2020. The promotion team is complemented by a highly capable and incentivized distribution team, which provides market penetration and national-level coverage. Since 2016, Macro Group has focused on growing its direct distribution channel and expand its coverage to pharmacies and wholesalers by establishing offices in Alexandria, Delta and Upper Egypt, with an eye to increase its cost efficiency, improve its cash conversion cycle and provide the Company with a continuous stream of market intelligence which feeds into formulating the future pipeline. Additionally, the Company implemented a GPS tracking system and an integrated CRM platform, which uses a specialized classification system in order to enable management to effectively monitor and manage its salesforce and to direct them to more profitable and high-potential segments.

Successful track record in launching new products

Since 2015, the Company has established a successful track record of new product launches across a variety of therapeutic areas. Building on strong growth from the Company's marketed portfolio, Macro Group expects recent and future new product launches to be a key driver of the future growth of the Company's business. Between 2015 and 2020, the Company launched 92 new products, representing 37% of revenues in 2020, with total value of new launches since 2015 up by a 2015-20 CAGR of 77%. The Company has extensive experience in expanding and diversifying its portfolio by utilizing its integrated business model, including its specialized R&D team, which aids the Company in continuously launching new products at attractive price points for customers in different demographic segments of the Egyptian population. Further, the dual positioning of the Company within the larger category of cosmetics and pharmaceuticals allows the Company to develop new and beneficial ingredients and formulae for new products in a cost efficient and rapid manner. As of 31 December 2020, the Company had 79 products in its pipeline to be launched between Q1 2021 and Q2 2023, across its seven high-growth cosmeceutical therapeutic areas as well as nutraceuticals.

Robust financial and operational performance

Macro Group has demonstrated strong financial performance over the last three years, with revenues up by a CAGR of 34% from EGP 240mn in 2018 to EGP 431mn in 2020, dual-driven by double-digit growth in both volume and pricing on the back of new product launches, an enhanced distribution network and newly implemented sales initiatives, all aimed at driving top line growth while improving its operating margins. The Company's focus on growing the contribution of its direct distribution channels, revising its salesforce incentive structure to promote and sell higher-margin products, and integrating its CRM system have all borne fruit, with marked improvements at both the gross profit and EBITDA levels. Economies of scale and improving cost-efficiencies have further helped solidify the Company's growth, with EBITDA up by a 2018-20 CAGR of 92% from EGP 51mn in 2018 to EGP 187mn in 2020, representing an EBITDA margin expansion of 22 pps to 43% (2018: 21%) over the period. Meanwhile, net profit almost quadrupled in value during the same period from EGP 34mn in 2018 to EGP 135mn in 2020, with its corresponding net profit margin up by 17 pps to record 31% in 2020 (2018: 14%).

Institutionalized and experienced management team

The Company benefits from a strong, cohesive management team with extensive multinational experience in the pharmaceutical and cosmeceutical industries, including with the major international companies in both Egypt and abroad. Collectively, the members of the Company's senior management team have over 200 years of experience gained at leading international companies such as Johnson & Johnson, Sanofi Aventis and Novartis and local and regional pharmaceutical companies such as Hikma, Tabuk Pharmaceutical, Takeda Pharmaceuticals and Pharco. The Company has achieved consistent top line growth since its inception, which is testament to its senior management's ability to lead the Company and execute the Company's strategies even through exceptional times in Egypt.

Strong commitment to high ESG standards

Macro Group has been actively pursuing high environmental and safety standards for its employees and other stakeholders. The Company is taking steps to integrate ESG factors into its production process, through energy saving, waste minimization, and switching to raw materials with lower environmental impact. With females comprising approximately 40% of its total workforce and approximately 29% in senior management positions, Macro Group continuously strives to achieve gender equality within its workplace and promotes equitable development throughout the organization via specialized training programs and workshops. Furthermore, the Company is an active player in the community by providing social welfare through targeted initiatives.

Clear and well-articulated growth strategy underpinned by a number of expansion pillars

Macro Group has set in motion a number of growth avenues with the ultimate objective to develop its brand equity, increase its top line, and enhance its margins:


- i) **Innovation and New Launches.** Macro Group will continue to leverage its well-established market research and concept development approach via its feedback network and extensive in-house innovation capabilities to further diversify its portfolio and better cater to all segments in the market.
- ii) **Nutraceuticals.** As a direct and synergistic complement to the Company's cosmeceuticals business with similarly attractive growth drivers, the nutraceuticals segment represents a promising addition to Macro Group. Utilizing an asset-light approach through toll manufacturing, the Company aims to leverage its existing platform and robust sales and distribution capabilities to capture a growing share of this fragmented market.
- iii) **Exports.** Macro Group's business model represents an opportunity for further expansion into similar markets which are highly populated and underpenetrated, and the Company is working to gain wider access to markets across the region, including Saudi Arabia and select African countries.
- iv) **DTC Channels.** Macro Group plans to target new sales channels for growth, emphasizing Direct to Consumer ("DTC") initiatives with an aim of cultivating greater control over its brand, engaging directly with consumers to gain valuable insight and expanding its market share.

Financial & Operational Highlights

The following table presents Macro Group's operational highlights for the years indicated⁹.

Income Statement Highlights	2018 EGP mn	2019 EGP mn	2020 EGP mn	18-20 CAGR/pps
Net Sales	240.0	383.7	430.5	34%
Gross Profit	151.8	288.9	338.1	49%
GP Margin	63.3%	75.3%	78.6%	+15 pps
EBITDA	50.8	146.7	186.5	92%
EBITDA Margin	21.2%	38.2%	43.3%	+22 pps
Net Profit	34.4	111.3	135.1	98%
NP Margin	14.3%	29.0%	31.4%	+17 pps

The following chart presents Macro Group's revenue by therapeutic area¹⁰ in terms of sales value and the corresponding 2-year CAGR for the years indicated.



⁹ The calculation for gross profit is based on cost of sales including depreciation and EBITDA is calculated as net profit before net finance cost, income tax expense, depreciation, amortization and impairment losses on financial assets

¹⁰ Excludes exports

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, CANADA, JAPAN OR ANY OTHER JURISDICTION WHERE IT IS UNLAWFUL TO DISTRIBUTE THIS ANNOUNCEMENT



Important Notice

The information contained in this announcement is for background purposes only and does not purport to be full or complete. No reliance may be placed by any person for any purpose on the information contained in this announcement or its accuracy, fairness or completeness.

The announcement is for informational purposes only and does not constitute an offer of securities for sale or a solicitation of any offer to buy securities in Egypt, the United States, Australia, Canada, Japan or any other jurisdiction in which such an offer or solicitation is unlawful. The distribution of this announcement may be restricted by law in certain jurisdictions and persons into whose possession any document or other information referred to herein comes should inform themselves about and observe any such restriction. Any failure to comply with these restrictions may constitute a violation of the securities laws of any such jurisdiction. The securities referred to herein have not been and will not be registered under the U.S. Securities Act of 1933, as amended (the "Securities Act"), or the laws of any state or other jurisdiction of the United States, and may not be offered or sold within the United States except pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the Securities Act and other applicable securities laws. No public offering of securities will be made in the United States. Subject to certain exceptions, the securities referred to herein may not be offered or sold in Australia, Canada or Japan, or for the account or benefit of, any national, resident or citizen of Australia, Canada or Japan. Copies of this announcement are not being, and should not be, distributed or sent into the United States, Australia, Canada or Japan. This announcement is an advertisement and not a prospectus and does not constitute or form a part of any offer or solicitation to purchase or subscribe for, or otherwise invest in, securities in any jurisdiction, including in Egypt, the United States, Australia, Canada, Japan or elsewhere. Any offer to acquire shares in the Company ("Shares") pursuant to the proposed International Offering will be made, and any investor in the International Offering should make his investment, solely on the basis of information that is contained in the Offering Circular. Any offer to acquire shares pursuant to the proposed Egyptian Retail Offering will be made, and any investor in the Egyptian Retail Offering should make his investment, solely on the basis of the information that is contained in the public subscription notice expected to be published by the Company after ratification by the FRA in due course (the "PSN").

This announcement and any offer if made subsequently is directed only at persons in member states of the European Economic Area ("EEA") who are "qualified investors" within the meaning of Article 2(e) of Regulation (EU) 2017/1129, as amended from time to time (the "Prospectus Regulation"), ("Qualified Investors"). In addition, in the United Kingdom, this announcement and any offer if made subsequently is directed only at Qualified Investors as defined in Article 2(e) of the Prospectus Regulation, as it forms part of domestic law by virtue of the European Union (Withdrawal) Act 2018, who are also (i) persons who have professional experience in matters relating to investments falling within the definition of "investment professionals" in Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (the "Order"), (ii) high net worth entities falling within Article 49(2) of the Order or (iii) other persons to whom it may lawfully be communicated (all such persons together being referred to as "relevant persons"). This announcement must not be acted on or relied on (i) in any member state of the European Economic Area, by any person who is not a Qualified Investor (ii) in the UK, by any person who is not a relevant person.

Any person in the EEA who acquires the securities in any offer (an investor) or to whom any offer of the securities is made will be deemed to have represented and agreed that it is a Qualified Investor. Any investor in the UK is deemed to have represented and agreed that it is a relevant person. Any investor will also be deemed to have represented and agreed that any securities acquired by it in the Offering have not been acquired on behalf of persons in the EEA other than Qualified Investors and other member states (where equivalent legislation exists) or relevant persons in the UK for whom the investor has authority to make decisions on a wholly discretionary basis, nor have the securities been acquired with a view to their offer or resale in the EEA to persons where this would result in a requirement for publication by the Company or any other manager of a prospectus pursuant to Article 3 of the Prospectus Regulation. The Company, CI Capital, Renaissance Capital, and their respective affiliates, and others will rely on the truth and accuracy of the foregoing representations and agreements.

This announcement does not constitute or form part of any offer or any solicitation to purchase nor shall it or the fact of its distribution, form the basis of, or be relied on in any purchase. Except for the Egyptian Retail Offering, the securities must not be offered, sold or purchased except in circumstances that do not constitute a public offering. This announcement and any subsequent offer of securities may be restricted by law in certain jurisdictions and persons receiving this announcement or any subsequent offer should inform themselves about and observe any restriction. Failure to comply with these restrictions may violate securities laws of certain jurisdictions.



In Egypt, the International Offering, when effected, will only be addressed to, and directed at "qualified individual investors", "public entities" or "qualified financial institutions" as defined in the FRA Board decision no. 48 for the year 2019. Prior to the approval of the public subscription notice by the Egyptian Financial Regulatory Authority ("FRA"), no information, which is normally included in public subscription notices or other promotional activities relating to the Offering may be released or conducted. However, following the submission of the public subscription notice to the FRA for approval, advertisements, circulars, letters and other information related to the Company's general business activities and the Offering may be released or distributed, provided that in all cases it is clearly indicated that the FRA has not yet approved the public subscription notice. This document does not constitute a public offering or a private placement of securities of any offer, which requires a license from the FRA. Investors in Egypt should only refer to and make purchases based solely in reliance on the PSN to be reviewed and approved by the FRA

Forward-Looking Statements

This announcement contains certain forward-looking statements. A forward-looking statement is any statement that does not relate to historical facts and events, and can be identified by the use of words and phrases like "according to estimates", "anticipates", "assumes", "believes", "could", "estimates", "expects", "intends", "is of the opinion", "may", "plans", "potential", "predicts", "projects", "should", "to the knowledge of", "will", "would" or, in each case their negatives or other similar expressions, which are intended to identify a statement as forward-looking. This applies, in particular, to statements containing information on future financial results, plans, or expectations regarding the Company's business and management, the Company's future growth or profitability and general economic and regulatory conditions and other matters affecting the Company.

Forward-looking statements reflect the current views of management of future events and are based on management's assumptions and involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of the Company to be materially different from any future results, performance or achievements expressed or implied by these forward-looking statements. The occurrence or non-occurrence of an assumption could cause the actual financial condition and results of operations of the Company to differ materially from, or fail to meet expectations expressed or implied by, those forward-looking statements. The Company's business is subject to a number of risks and uncertainties that could also cause a forward-looking statement, estimate or prediction to become inaccurate. These risks include fluctuations in the prices of energy, raw materials or employee costs required by the operations of the Company, its ability to retain the services of certain key employees, its ability to launch and create demand for new products, its ability to compete successfully, changes in political, social, legal, regulatory, economic conditions in Egypt, developments related to the COVID-19 pandemic, worldwide and Egyptian economic and business trends, adverse legal decisions, the impact of war, unrest and terrorist activity, inflation, interest rate and exchange rate fluctuations, the Company's ability to rely on official statistics and market data and the ability of management to identify accurately and in a timely manner future risks to the business of the Company and manage the risks mentioned above.

Accordingly, investors should not rely on the forward-looking statements in this announcement. None of the Company, its management, CI Capital, and Renaissance Capital or any of their respective advisors, give any assurance regarding the future accuracy of the opinions set forth in this announcement or as to the actual occurrence of any predicted developments. After the date of this announcement, none of the Company or its management assumes, and each of the Company and its management expressly disclaim, any obligation, except as required by law and the Listing Rules of the EGX, to update any forward-looking statements or to conform these forward-looking statements to the actual results of the Company. Each of CI Capital, and Renaissance Capital and their respective affiliates as defined under Rule 501(b) of Regulation D under the Securities Act ("affiliates"), expressly disclaims any obligation or undertaking to update, review or revise any forward-looking statement contained in this announcement whether as a result of new information, future developments or otherwise.

* * *

Any subscription or purchase of Shares in the possible Offering should be made solely on the basis of information contained in the Offering Circular, which may be issued by the Company in connection with the possible Offering. The information in this announcement is qualified in its entirety by the information expected to be set out in the Offering Circular (in the case of the International Offering) and the PSN (in respect of the Egyptian Retail Offering) and subject to change. The Company expressly does not undertake to update the information in this announcement. Before subscribing for or purchasing any Shares, persons viewing this announcement should ensure that they fully understand

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, CANADA, JAPAN OR ANY OTHER JURISDICTION WHERE IT IS UNLAWFUL TO DISTRIBUTE THIS ANNOUNCEMENT



and accept the risks which will be set out in the Offering Circulars if published. No reliance may be placed for any purpose on the information contained in this announcement or its accuracy or completeness. Neither this announcement, nor anything contained herein, shall form the basis of or constitute any offer or invitation to sell or issue, or any solicitation of any offer to purchase or subscribe for any Shares or any other securities nor shall it (or any part of it) or the fact of its distribution, form the basis of, or be relied on in connection with, any contract therefor.

The date of IPO (if it proceeds) may be influenced by a variety of factors, which include, among other things, market conditions. Macro Group may decide not to go ahead with the IPO, and there is, therefore, no guarantee that IPO will occur at all or in accordance with the timing indicated in this announcement. Potential investors should not base their financial decision on this announcement. Acquiring investments to which this announcement relates may expose an investor to a significant risk of losing all of the amount invested.

Persons considering making investments should consult an authorised person specialising in advising on such investments. Neither this announcement, nor the documents referred to herein, constitutes a recommendation concerning a possible offer. The value of Shares can decrease as well as increase, and potential investors must be able to bear the risk of loss, including a total loss, on their investments. Potential investors should consult a professional advisor as to the suitability of a possible offer for the person concerned. None of CI Capital and Renaissance Capital, or any of their respective affiliates or any of their or their affiliates' directors, officers, employees, advisers or agents accepts any responsibility or liability whatsoever for/ or makes any representation or warranty, express or implied, as to the truth, accuracy or completeness of the information in this announcement (or whether any information has been omitted from the announcement) or any other information relating to the Company, its subsidiaries or associated companies, whether written, oral or in a visual or electronic form, and howsoever transmitted or made available or for any loss howsoever arising from any use of the announcement or its contents or otherwise arising in connection therewith.

Each of CI Capital and Renaissance Capital is acting exclusively for the Issuer and no one else in connection with the possible Offering. They will not regard any other person as their respective clients in relation to the possible Offering and will not be responsible to anyone other than the Company for providing the protections afforded to their respective clients, nor for providing advice in relation to the possible Offering, the contents of this announcement or any transaction, arrangement or other matter referred to herein.

CI Capital and Renaissance Capital are regulated by the Financial Regulatory Authority in the Arab Republic of Egypt.

In connection with the possible Offering, each of CI Capital and Renaissance Capital and any of their respective affiliates, may take up a portion of the Shares as a principal position and in that capacity may retain, purchase, sell, offer to sell or otherwise deal for their own accounts in such Shares and other securities of the Issuer or related investments in connection with the possible Offering or otherwise. Accordingly, references in the Offering Circulars, once published, to the Shares being issued, offered, subscribed, acquired, placed or otherwise dealt in should be read as including any issue or offer to, or subscription, acquisition, placing or dealing by any of CI Capital and Renaissance Capital and any of their respective affiliates acting in such capacity. In addition, CI Capital and Renaissance Capital and any of their respective affiliates may enter into financing arrangements (including swaps or contracts for differences) with investors in connection with which they may from time to time acquire, hold or dispose of Shares. None of CI Capital and Renaissance Capital nor any of their respective affiliates intend to disclose the extent of any such investment or transactions otherwise than in accordance with any legal or regulatory obligations to do so.

For the avoidance of doubt, the contents of Macro Group's website are not incorporated by reference into, and do not form part of, this announcement.